Compare OFLX & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFLX | QTTB |
|---|---|---|
| Founded | 1975 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.9M | 265.2M |
| IPO Year | 2005 | 2018 |
| Metric | OFLX | QTTB |
|---|---|---|
| Price | $25.96 | $8.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $39.67 |
| AVG Volume (30 Days) | 39.0K | ★ 519.2K |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $98,296,000.00 | $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $150.00 |
| P/E Ratio | $37.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.99 | $1.91 |
| 52 Week High | $37.92 | $23.57 |
| Indicator | OFLX | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 56.04 | 46.44 |
| Support Level | $24.67 | $7.45 |
| Resistance Level | $26.97 | $9.16 |
| Average True Range (ATR) | 0.95 | 0.50 |
| MACD | 0.23 | 0.21 |
| Stochastic Oscillator | 67.29 | 71.54 |
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States. The company derives revenues from the manufacture and sale of flexible metal hose and accessories.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).